SMN1 and proximal spinal muscular atrophy: ,6 To this end, significant side effects have been observed with the market-approved gene therapeutic Zolgensma, which uses AAV9 to deliver a functional copy of the SMN1 gene for the treatment of spinal muscular atrophy (SMA).